Table 4 A breakdown of adverse and serious adverse events noted across all sites in the MATE trial and the number of patients affected. Patients with multiple adverse events in a particular category were only counted once in that category

AEs (total no. of patients)

16 (19)

18 (20)

Cardiac disorders

1

1

Ear & labyrinth disorders

1

2

Eye disorders

16

14

Gastrointestinal disorders

4

5

General disorders & administration site conditions

3

4

Hepatobiliary disorders

1

0

Infections & infestations

10

9

Injury, poisoning & procedural complications

7

4

Investigations

0

1

Musculoskeletal & connective tissue disorders

3

5

Neoplasms; benign, malignant & unspecified

1

0

Nervous system disorders

5

1

Reproductive system & breast disorders

0

1

Respiratory, thoracic & mediastinal disorders

3

2

Skin & subcutaneous tissue disorders

4

2

Surgical & medical procedures

3

5

Vascular disorders

1

2

SAEs (total no. of patients)

9 (19)

8 (20)

Cardiac disorders

3

1

Ear & labyrinth disorders

0

1

Eye disorders

1

0

Gastrointestinal disorders

1

1

Hepatobiliary disorders

2

0

Infections & infestations

3

2

Injury, poisoning & procedural complications

2

2

Neoplasms; benign, malignant & unspecified

2

2

Nervous system disorders

0

2

Renal & urinary disorders

1

1

Respiratory, thoracic & mediastinal disorders

0

2

Vascular disorders

1

0